Inclusion Criteria:

- Diagnosis of locally advanced or metastatic colorectal cancer.

- No prior chemotherapy for metastatic disease.

- Presence of radiologically and/or clinically documented disease.

- Eastern Cooperative Oncology Group performance status of 0 or 1.

- Adequate bone marrow, hepatic, renal function, Urine Creatinine Ratio (UPC) of <

- A female subject must not be pregnant or breast feeding.

- Able to swallow and retain oral medications.

Exclusion Criteria:

- Has had any major surgery, chemotherapy, hormone therapy, investigational agent, or
radiotherapy within the last 28 days

- Prior treatment with pazopanib, or oxaliplatin.

- Known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or
folinic acid.

- Participation in any investigational study within 28 days prior to study treatment.

- Women who are pregnant or lactating.

- Poorly controlled hypertension.

- A history of cardiovascular disease, arrhythmias, or significant ECG abnormalities.

- Any history of stroke.

- Current use of therapeutic warfarin.

- Known brain metastases.

- History of disease significantly affecting gastrointestinal function or major
resection of the stomach or small bowel.

- Active infections or other serious illness.

- History of allergy to platinum compounds or heparin.

- Poor venous access.